Document Classification

Section Type: RESULTS

Text: Of the patients in the candesartan group, 817 (35. 7 %) experienced cardiovascular death or a CHF hospitalization as compared with 944 (41. 3 %) in the placebo group (HR 0. 82 ; 95 % CI 0. 74 to 0. 90 ; P < 0. 001) with reduced risk for both cardiovascular deaths (521 [22. 8 %] versus 599 [26. 2 %] ; HR 0. 84 [95 % CI 0. 75 to 0. 95] ; P = 0. 005) and CHF hospitalizations (516 [22. 5 %] versus 642 [28. 1 %] ; HR 0. 76 [95 % CI 0. 68 to 0. 85] ; P < 0. 001).